MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation"

MaaT Pharma published retrospective data on acute graft-versus-host disease (aGvHD) in the journal "Bone Marrow Transplantation". This data comes from the CHRONOS study, which evaluated 59 patients with refractory gastrointestinal aGvHD treated with third-line therapies other than microbiota therapy.

This study highlights the need for new therapeutic options for patients resistant to current treatments. The CHRONOS results show an overall survival rate of 29% at 12 months and an overall response rate of 37% at Day 28, indicating limited benefits with existing therapies.

MaaT Pharma has incorporated these results into its Marketing Authorisation Application for MaaT013 (Xervyteg®), which is currently under review by the European Medicines Agency (EMA). The EMA's decision is expected by mid-2026.